Home > Journals > Minerva Medica > Past Issues > Articles online first > Minerva Medica 2020 May 14

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

 

Minerva Medica 2020 May 14

DOI: 10.23736/S0026-4806.20.06616-1

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

Hyper-immune/convalescent plasma: an old option and a valid strategy for treatment of COVID-19?

Daniele SAVERINO 1, 2

1 Department of Experimental Medicine, University of Genoa, Genoa, Italy; 2 Ospedale Policlinico San Martino, Genoa, Italy


PDF


Currently, there are no approved specific antiviral agents for novel coronavirus disease (COVID-19). Hyper-immune/convalescent plasma derived from recently recovered donors seems to be useful to treat COVID-19 patients, an addition to maximal supportive care and antiviral agents. The endpoints are the improvement of clinical symptoms and laboratory parameters of these patients. However, the efficacy of hyper-immune/convalescent plasma treatment for severe infectious diseases is still controversial. The optimal dose and time point, as well as the clinical benefit of hyper- immune/convalescent plasma therapy, needs further investigation in larger well-controlled trials.


KEY WORDS: Hyperimmune plasma; COVID-19; Therapeutic strategy

top of page